Skip to main content
. Author manuscript; available in PMC: 2014 Jul 5.
Published in final edited form as: Int J Low Extrem Wounds. 2011 Aug 19;10(3):122–129. doi: 10.1177/1534734611418157

Fig. 3. Control immunostaining for K1, K10 and K17 in normal skin and basal cell carcinoma.

Fig. 3

Intense immunostaining for (A) K1 and (B) K10 is present in the suprabasal keratinocytes of normal control skin (no immunostaining is detectable in the basal cell layer. 20×. (C) The dermal tumor aggregates of basal cell carcinoma show intense immunostaining for K17, while faint suprabasilar immunostaining is present in the overlying epidermis. 20×.